EU Commission approves Eylea for CRVO
Bayer HealthCare announced that Eylea (aflibercept solution for injection) has been approved by the European Commission for the treatment of visual impairment due to Macular Edema secondary to Central Retinal Vein Occlusion (CRVO).
�The results of the two phase III studies (COPERNICUS and GALILEO) were encouraging with the majority of patients with Macular Edema secondary to Central Retinal Vein Occlusion experiencing a significant improvement in visual acuity with Eylea,� said Frank G. Holz, M.D., Professor at the Department of Ophthalmology, University of Bonn, Germany and Lead Principal Investigator of the GALILEO trial.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.